Fullerton Fund Management Co Ltd. Grows Stock Holdings in Boston Scientific Corporation $BSX

Fullerton Fund Management Co Ltd. lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 184.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 598,174 shares of the medical equipment provider’s stock after purchasing an additional 387,761 shares during the period. Boston Scientific makes up approximately 2.5% of Fullerton Fund Management Co Ltd.’s investment portfolio, making the stock its 15th biggest position. Fullerton Fund Management Co Ltd.’s holdings in Boston Scientific were worth $57,036,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of BSX. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter valued at $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific in the 4th quarter valued at $26,000. Colonial Trust Co SC increased its holdings in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 231 shares during the last quarter. Bangor Savings Bank increased its holdings in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund bought a new stake in Boston Scientific in the 4th quarter valued at $29,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Edward J. Ludwig bought 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 9,800 shares of company stock worth $554,012 in the last three months. Insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

Boston Scientific stock opened at $46.92 on Wednesday. The company’s 50-day moving average price is $55.74 and its 200-day moving average price is $74.02. Boston Scientific Corporation has a twelve month low of $45.99 and a twelve month high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The company has a market cap of $69.74 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the previous year, the firm posted $0.75 EPS. The business’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its board has approved a share repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

BSX has been the topic of a number of research reports. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a report on Thursday, April 23rd. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Raymond James Financial reiterated an “outperform” rating and issued a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Finally, The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $85.08.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.